[The present state and prospect of genomic drug discovery].
Genomics and its technologies are being integrated into drug discovery research for three purposes; to find novel target molecules, to evaluate pharmaceutical efficacy and safety on a genome scale, and to select patients in terms of their genetic polymorphisms. Search for novel targets has been focused on G protein-coupled receptors and enzyme families such as protein kinases, protein phosphatases and proteases. The targets selected are validated in vivo with knockout mice or by administration with antibodies or antisense nucleotide derivatives. In connection with the validation, chronology on anti-platelet therapeutics through antibodies is referred to. Among genomic polymorphisms on drug response of patients, those of drug metabolizing enzymes are important for personalized medicine. Lastly, diversification of therapeutics aiming at personalized medicine is discussed in comparison with diversities of automobiles and living creatures, suggesting a novel concept, 'digital medicine'.
Masuho
Yasuhiko
Y
Helix Research Institute, Inc.
D000818:Animals; D015195:Drug Design; D019204:GTP-Binding Proteins; D016678:Genome; D006801:Humans; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011494:Protein Kinases; D011956:Receptors, Cell Surface
D011956:Receptors, Cell Surface; D011494:Protein Kinases; D019204:GTP-Binding Proteins